Rijkaart van Cappellen di Amsterdam (Pasi Bassi) in data 10 novembre 2021 e debitamente apostilla- to portante il cambio della denominazione della Società in "Avient S.à r.l.". Sono stati allegati al suddetto documento: - il consenso espresso per iscritto dal Consiglio di Ammini- strazione della Società, redatta in inglese, debitamente au- tenticata e apostillata; - copia conforme della delibera del socio unico in data 8 no- vembre 2021, redatta in doppia lingua inglese e francese, de- bitamente autenticata e apostillata; - lo statuto aggiornato della Società, redatto in doppia lin- gua inglese e francese, debitamente apostillato; 2. estratto della Società dal Registro delle Società e del Commercio del Lussemburgo in data 12 novembre 2021, redatto in lingua francese e debitamente apostillato, portante la nuova denominazione sociale.

Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • 18 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth Confirmation of Our Strategy The World’s Premier Provider of Specialized Polymer Materials, Services and Solutions Specialization Globalization Operational Excellence Commercial Excellence -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% 450.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $39.28 April 4th, 2014 • 18 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 6 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 7 PolyOne At A Glance United States 67% Europe 14% Canada 7% Asia 6% Latin America 6% Specialty 54% PP&S 18% Distribution 28% Mix Shift Highlights Specialty Transformation Page 8 Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 64% 0% 20% 40% 80% 2005 2008 2010 2013 Q1 2014 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty 65-75% Specialty OI $5M $46M $87M $195M $60M Target 2015 Target Proof of Performance & 2015 Goals Page 9 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 42.0% 2006 Q1 2014 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Investing in operational and initiatives that drive profitability growth Manufacturing realignment  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?  Strong past performance demonstrates that our strategy and execution are working  Megatrends and emerging opportunities align with our strengths  Innovation and services provide differentiation, incremental pricing power, and competitive advantage  Strong and proven management team driving growth and performance  Addressable market exceeds $40 billion Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S.

Thanks to our strong supplier relationships, we are typically aware of these changes ahead of time and often will have an alternative formulated before discontinuation affects the supply chain.

As a professional supplier for packaging film and sheet, Avient offers a wide range of functional additives for flexible materials, which can be specifically designed to meet the demanding requirements for different industries.

Data Protection. The parties undertake to carry out the processing of personal data necessary to comply with the Terms in compliance with the General Law for the Protection of Personal Data (Law No. 13.709/2018, "LGPD") and regulations currently issued, or that are issued in the future, by the National Data Protection Authority ("ANPD"), under penalty of fine, without prejudice of losses and damages that the other party may incur. The Buyer represents that it will obtain prior consent of the owner of any data shared with the Seller so that such data may be used by the Seller as necessary for the purposes of these Terms. 21.

He is responsible for enabling business strategies through innovative tools, data, digitalization, and artificial intelligence while ensuring the security of data and systems.

Avient is committed to replacing, reducing and refining the use of animal testing by applying the following practices: • Replace – Before any vertebrae testing, Avient will investigate the use of alternative methods and approaches, including use of data that is already publically available, computational toxicology models and read-across to available data for similar substances

Our filings are available to the public at the SEC’s website at http://www.sec.gov. SELECTED FINANCIAL DATA ITEM 7. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ITEM 9.

CENTRALNA INFORMACJA KRAJOWEGO REJESTRU SĄDOWEGO KRAJOWY REJESTR SĄDOWY Stan na dzień 12.04.2021 godz. 13:58:52 Numer KRS: 0000108922 Informacja odpowiadająca odpisowi aktualnemu Z REJESTRU PRZEDSIĘBIORCÓW Data rejestracji w Krajowym Rejestrze Sądowym 23.04.2002 Ostatni wpis Numer wpisu 55 Data dokonania wpisu 12.04.2021 Sygnatura akt LD.XX NS-REJ.KRS/10228/21/64 Oznaczenie sądu SĄD REJONOWY DLA ŁODZI ŚRÓDMIEŚCIA W ŁODZI, XX WYDZIAŁ GOSPODARCZY KRAJOWEGO REJESTRU SĄDOWEGO Dział 1 Rubryka 1 ­ Dane podmiotu 1.Oznaczenie formy prawnej SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ 2.Numer REGON/NIP REGON: 470520600, NIP: 7320000991 3.Firma, pod którą spółka działa AVIENT COLORANTS POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ 4.Dane o wcześniejszej rejestracji RHB 3264 SĄD REJONOWY DLA ŁODZI-ŚRÓDMIEŚCIA W ŁODZI 5.Czy przedsiębiorca prowadzi działalność gospodarczą z innymi podmiotami na podstawie umowy spółki cywilnej? 7.Data do jakiej została zawieszona ­­­­­­ 2 1.Nazwisko / Nazwa lub Firma OLEJNICZAK 2.Imiona JOLANTA AGNIESZKA 3.Numer PESEL/REGON 81071008348 4.Numer KRS **** 5.Funkcja w organie reprezentującym CZŁONEK ZARZĄDU Strona 3 z 8 6.Czy osoba wchodząca w skład zarządu została zawieszona w czynnościach? 7.Data do jakiej została zawieszona ­­­­­­ Rubryka 2 ­ Organ nadzoru Rubryka 3 ­ Prokurenci 1 1.Nazwisko CIULĘBA 2.Imiona TOMASZ 3.Numer PESEL 77030712078 4.Rodzaj prokury PROKURA OBEJMUJĄCA UMOCOWANIE WYŁĄCZNIE DO DOKONYWANIA CZYNNOŚCI WSPÓLNIE Z CZŁONKIEM ZARZĄDU.